The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3
Open accessAbstract
Patients with neuroendocrine carcinomas (NECs) grade 3 have a poor prognosis. Etoposide–platinum combination is the standard chemotherapy but the role of a second-line therapy remains unknown. Irinotecan alone or in combination has shown some efficacy in patients treated for small cell lung cancer which had pathological similarities with neuroendocine tumors. The aim of this study is to determine safety and efficacy of the FOLFIRI regimen in patients with NECs grade 3 after failure of etoposide–platinum combination. This study was retrospective, including patients with NECs grade 3 and treated with the FOLFIRI regimen after progression or toxicity of etoposide–platinum combination in first-line. Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≥3 and/or serum alkaline phosphatase ≥5×upper limit of normal value (ULN) and/or bilirubin ≥1.5×ULN were excluded. Among 39 patients who failed etoposide–platinum combination, 19 (49%; 12 women, median age 53 (29–78) years) received the FOLFIRI regimen with a median number of 6 (1–16) courses. Six patients (31%) had at least one episode of grades 3–4 toxicity (neutropenia, n=3; diarrhea, n=3) without toxic death. Six patients (31%) had objective response, 6 (31%) stable disease, and 7 (38%) tumor progression. Median progression-free survival under FOLFIRI was 4 months. Overall survival was 18 vs 6.8 months in noneligible patients. FOLFIRI regimen is a safe and potentially efficient chemotherapy given as second-line in patients with NECs grade 3 who remain in good condition and with correct liver tests after failure of etoposide–platinum combination. These results should be confirmed in a future prospective study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Cited by
Pavel, M., O''Toole, D., Costa, F., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E., Knigge, U., Salazar, R., Pape, U.-F., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,041
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 619
Garcia-Carbonero, R., Sorbye, H., Baudin, E., Raymond, E., Wiedenmann, B., Niederle, B., Sedlackova, E., Toumpanakis, C., Anlauf, M., Cwikla, J. B., et al. (2016) · Neuroendocrinology · doi:10.1159/000443172 · Cited by 611
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R., Murphy, K., Haberkorn, U., & Morgenstern, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2857-9 · Cited by 407
Metadata
- Authors
- Hentic, O., Hammel, P., Couvelard, A., Rebours, V, Zappa, M., Palazzo, M., Maire, F., Goujon, G., Gillet, A., Lévy, P., & Ruszniewski, P.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2012-08-31
- Volume
- 19
- Issue
- 6
- Pages
- 751-757
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2169749676
- Cited by
- 162
- References
- 1
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3. https://app.cochat.ai/papers/10.1530/erc-12-0002
- The paper
- Hentic, O., Hammel, P., Couvelard, A., Rebours, V, Zappa, M., Palazzo, M., Maire, F., Goujon, G., Gillet, A., Lévy, P., & Ruszniewski, P. (2012). FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3. Endocrine-Related Cancer. https://doi.org/10.1530/erc-12-0002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.